Skip to main content

Table 3 Adverse events of any cause (reported in 10% or more of patients, N = 34)

From: A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Adverse events

All grades, N (%)

Grade 3 or 4, N (%)

 Stomatitis

27 (79.4)

1 (2.9)

 Anemia

22 (64.7)

1 (2.9)

 Asthenia

13 (38.2)

2 (5.9)

 Leukopenia

11 (32.4)

1 (2.9)

 Neutropenia

10 (29.4)

0 (0.0)

 Rash

10 (29.4)

0 (0.0)

 Infection

8 (23.5)

2 (5.9)

 Nausea

5 (14.7)

0 (0.0)

 Dyspnea

5 (14.7)

0 (0.0)

 Anorexia

5 (14.7)

0 (0.0)

 Thrombocytopenia

4 (11.8)

0 (0.0)

 Epistaxis

4 (11.8)

0 (0.0)

 Cough

4 (11.8)

0 (0.0)